(RTTNews) – The general variety of coronavirus times shown has exceeded 1 million, with more than 602,000 deaths recorded to date, Johns Hopkins University. Researchers and pharmaceutical corporations are competing against the clock not only to expand remedies for COVID-19, but also vaccines that can also help long-term logical pandemics.
According to the WHO database, 23 COVID-1nine vaccine applicants have complexes in clinical trials.
US company Apple Moderna Inc. (MRNA), the first to transfer its COVID-1nine mRNA-1273 vaccine candidate to humans in March, reported an interim positive clinical knowledge of its Phase I study in May. A Phase II study of the vaccine is underway and a Phase III study is expected to begin the month.
Gam-COVID-Vac, a coronavirus vaccine being developed through the Russian Institute of Epidemiology and Microbiology Gamaleya Reseek, has entered the general phase of clinical trials. Russia could be the first to deploy a coronavirus vaccine to the fullest of the population in early August, according to TASS, the Russian news agency.
AstraZeneca PLC (AZN)
AstraZeneca is preparing a vaccine against cornoavirus called AZD1222, in part with the University of Oxford.
Data from the phase I trial of the azD1222 coronavirus vaccine candidate are expected to be published in the medical journal The Lancet on Monday, July 20.
The vaccine has already entered the Phase II and Phase III trials in the UK, and phase III trials are expected to be announced in Brazil later this year.
Pfizer (PFE) / BioNTech (BNTX)
Pfizer and BioNTech’s mRN-founded vaccination program for SARS-CoV-2 called BNT162 includes four applicants for experimental intellectual vaccines and the maximum complex of the four is BNT162b1.
BNT162 is undergoing Phase I/II testing in Europe. On July 1, the companies reported that they encouraged initial U.S. knowledge. From phase I test of BNT162b1. Additional knowledge of Gerguy’s essay for BNT162b1 is expected in mid-July.
The launch of a large-scale Phase IIb/III trial of the desperate vaccine candidate number one is expected by the end of July, the subject for regulatory approval.
CytoDyn Inc. (CYDY. OB)
CytoDyn is testing Leronlimab, its humanized monoclonal antibody, as a prospective therapy for COVID-1nine in two clinical trials: a mild to moderate COVID-1nine Phase II clinical trial and a Phase III trial in severe and COVID-1nine critical patients. .
Test updates must be submitted this month.
Recently, the compabig apple filed a full application with the Nasdaq Stock Market to request a design in its non-common actions.
Novavax Inc. (NVAX)
Novavax NVX-CoV2373 vaccine candidate as opposed to COVID-1nine is undergoing a phase I trial. The Phase I trial was announced in May, and initial immune and defense effects are expected this month.
If the effects are promising, the Phase II component of the test can be quickly announced. A phase III fundamental test of NVX-CoV2373 with up to 30,000 subjects is expected to begin in the fall of 2020.
NVAX closed On Friday at $140.49, up 16.79%.